What is Awakn Life Sciences?

Addiction is one of the world’s biggest unmet medical needs. Substance and behavioural addictions affect over 1.3¹ billion people worldwide. Yet all current treatments have high failure rates.

Fortunately, Ken Starr MD is partnering with Awakn Life Sciences, a clinical-stage biotechnology company developing proprietary therapeutics to treat addiction, with a near-term focus on Alcohol Use Disorder. 

Awakn is developing a better solution to treat addiction: psychedelic therapeutics, drugs, and therapies used in combination.  

Through clinical trials, the Awakn team has shown that this approach has the potential to be more effective than any addiction treatment currently available. They aspire to become the market leader in effective addiction treatment, meeting a vast global need that is failed by current approaches.